2-bromo-1-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)ethanone | 1014-18-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2-bromo-1-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)ethanone
• 英文别名: 2-bromo-1-(1,4-benzodioxan-2-yl)ethanone；2-(bromoacetyl)-1,4-benzodioxan；bromacetyl-2 benzodioxanne；2-bromo-1-(2,3-dihydro-benzo[1,4]dioxin-2-yl)-ethanone；2-bromacetyl 2,3-dihydro [4H] 1,4-benzodioxin；2-(2-bromoacetyl)-1,4-benzodioxan；Ethanone, 2-bromo-1-(2,3-dihydro-1,4-benzodioxin-2-yl)-；2-bromo-1-(2,3-dihydro-1,4-benzodioxin-3-yl)ethanone
• CAS: 1014-18-2
• 化学式: C₁₀H₉BrO₃
• mdl: MFCD04972619
• 分子量: 257.084
• InChiKey: XHYCSCBAALGUBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2932999099

SDS

Name:	2-Bromo-1-(2 3-dihydro-1 4-benzodioxin-2-yl)-1-ethanone 97% Material Safety Data Sheet
Synonym:
CAS:	1014-18-2

Section 1 - Chemical Product MSDS Name:2-Bromo-1-(2 3-dihydro-1 4-benzodioxin-2-yl)-1-ethanone 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1014-18-2	2-Bromo-1-(2,3-dihydro-1,4-benzodioxin	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1014-18-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 99 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9BrO3
Molecular Weight: 257.08

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1014-18-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Bromo-1-(2,3-dihydro-1,4-benzodioxin-2-yl)-1-ethanone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 1014-18-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1014-18-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1014-18-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)ethanone 在 甲醇 、 sodium tetrahydroborate 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 生成 d,l-erythro-2-oxiranyl-2,3-dihydro-1,4-benzodioxin
  参考文献：
  名称：

  [EN] NOVEL CYCLIC PHENOXY COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE
  [FR] NOUVEAUX COMPOSÉS PHÉNOXY CYCLIQUES ET TRAITEMENTS AMÉLIORÉS POUR UNE MALADIE CARDIAQUE ET CARDIOVASCULAIRE

  摘要：

  化学式I的化合物，及其在游离形式或盐形式中的药学上可接受的盐或盐和生理水解衍生物：（化学式（I））其中Q1，CR6a和可选的R6b共同形成一个环状基团，其中：Q1选自C1-2烷基，C1-2烯基，OC1烷基和OC1烯基基团，可选择地被氧代取代；R6a是一个单键，R6b是H；或者R6a和R6b共同形成一个双键；Q2和Q3分别选自H，R1和R2；或者Q2和Q3共同形成一个环状基团，在该环状基团中，Q2和Q3中的一个是选自OC1烷基和OC1烯基基团，可选择地被氧代取代或由下文定义为R2的基团R5的环状基团，而另一个是选自C1-2烷基，C1-2烯基和OC1烷基，可选择地被氧代取代；R6a和R6b分别为H或如上定义的环状基团；Q1选自H，R1和R2以及如上定义的环状基团；R1-4为H或取代基；Z选自线性C2-3烷基；X3为NH；R7-9为H或取代基；它们的制备和新颖中间体，其组成物及其在心脏和心血管疾病的预防或治疗中的用途以及治疗方法。

  公开号：

  WO2013121209A1
• 作为产物：
  描述：

  2,3-二氢苯并[1,4]二恶烷-2-甲腈 在 溴 、 碘 、 magnesium 、 calcium carbonate 作用下， 以 乙醚 、 正己烷 、 苯 为溶剂， 反应 8.0h， 生成 2-bromo-1-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)ethanone
  参考文献：
  名称：

  Synthesis and biologic properties of new thiazolylbenzodioxane derivatives

  摘要：

  Reaction of 4-(1,4-benzodioxan-2-yl)thiazol-2-amine with acid chlorides afforded N-substituted amides which further were reduced into the corresponding amines. A new method was developed of preparation of 2-acetyl-1,4-benzodioxane, the initial compound in the synthesis of thiazolylbenzodioxane and numerous derivatives of this series. The adreno- and sympatholytic as well as antihypoxic effect of the obtained biheterocyclic 1,4-benzodioxane derivatives were investigated.

  DOI：

  10.1134/s1070428016020159

文献信息

• [EN] NOVEL CYCLIC PHENOXY COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE<br/>[FR] NOUVEAUX COMPOSÉS PHÉNOXY CYCLIQUES ET TRAITEMENTS AMÉLIORÉS POUR UNE MALADIE CARDIAQUE ET CARDIOVASCULAIRE
  申请人：UNIV NOTTINGHAM

  公开号：WO2013121209A1

  公开（公告）日：2013-08-22

  A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: (Formula (I)) wherein either Q1, CR6a and optionally R6b together form a cyclic moiety wherein: Q1 is selected from C1-2 alkylene, C1-2 alkenylene, OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo; R6a is a single bond and R6b is H; or R6a and R6b together form a double bond; and Q2 and Q3 are independently selected from H, R1 and R2; or Q2 and Q3 together form a cyclic moiety in which one of Q2 and Q3 is a cyclic moiety selected from OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo or a group R5 as hereinbelow defined for R2 and the other of Q2 and Q3 is a cyclic moiety selected from C1-2 alkylene, C1-2 alkenylene and OC1 alkylene optionally substituted by oxo; R6a and R6b are each H or a cyclic moiety as defined above; and Q1 is selected from H, R1 and R2 and a cyclic moiety as defined above; and R1-4 are H or substituents; Z is selected from linear C2-3 alkylene; X3 is NH; R7-9 are H or substituents; their preparation and novel intermediates, compositions thereof and their use in the prevention or treatment of cardiac and cardiovascular disease and methods for the treatment thereof.

  化学式I的化合物，及其在游离形式或盐形式中的药学上可接受的盐或盐和生理水解衍生物：（化学式（I））其中Q1，CR6a和可选的R6b共同形成一个环状基团，其中：Q1选自C1-2烷基，C1-2烯基，OC1烷基和OC1烯基基团，可选择地被氧代取代；R6a是一个单键，R6b是H；或者R6a和R6b共同形成一个双键；Q2和Q3分别选自H，R1和R2；或者Q2和Q3共同形成一个环状基团，在该环状基团中，Q2和Q3中的一个是选自OC1烷基和OC1烯基基团，可选择地被氧代取代或由下文定义为R2的基团R5的环状基团，而另一个是选自C1-2烷基，C1-2烯基和OC1烷基，可选择地被氧代取代；R6a和R6b分别为H或如上定义的环状基团；Q1选自H，R1和R2以及如上定义的环状基团；R1-4为H或取代基；Z选自线性C2-3烷基；X3为NH；R7-9为H或取代基；它们的制备和新颖中间体，其组成物及其在心脏和心血管疾病的预防或治疗中的用途以及治疗方法。
• 2-Piperidinoalkyl-1,4-benzodioxans
  申请人：Ciba-Geigy Corporation

  公开号：US04039676A1

  公开（公告）日：1977-08-02

  2-Piperidinoalkyl-1,4 benzodioxans, e.g. those of the formula ##STR1## AND ACID ADDITION SALTS THEREOF ARE NEUROLEPTIC AGENTS.

  2-哌啶基烷基-1,4-苯并二噁烷，例如式##STR1##及其酸盐是神经阻滞剂。
• Neuroleptic 2-piperidinoalkyl-1,4-benzodioxans
  申请人：Ciba-Geigy Corporation

  公开号：US04129655A1

  公开（公告）日：1978-12-12

  2-Piperidinoalkyl-1,4-benzodioxans, e.g. those of the formula ##STR1## and acid addition salts thereof are neuroleptic agents.

  2-哌啶基烷基-1,4-苯并二氧杂环己烷，例如式##STR1##及其酸盐是神经阻滞剂。
• Antihypertensive ureidopiperidines
  作者：J. L. Archibald、D. R. Beardsley、G. M. F. Bisset、P. Fairbrother、J. L. Jackson、A. Opalko、T. J. Ward

  DOI：10.1021/jm00182a009

  日期：1980.8

  These compounds are related to the benzamidopiperidines exemplified by indoramin. Some of the ureidopiperidines are more potent antihypertensive agents than their benzamidopiperidine counterparts. Two examples, 1-(2-thenoyl)-3-[1-[2-(3-indolyl)ethyl]piperid-4-yl]urea and 1-(2-thenoyl)-3-[1-[4-(4-fluorophenyl)-4-oxobutyl]piperid-4-yl]urea (19 and 58), emerged as the most potent antihypertensive agents

  报道了一系列1-芳烷基-4-脲基哌啶的合成。这些化合物与吲哚胺为例的苯甲酰氨基哌啶有关。一些脲基哌啶比其苯甲酰氨基哌啶具有更强的抗高血压药。两个例子，1-（2-thenoyl）-3- [1- [2-（3-吲哚基）乙基]哌啶-4-基]脲和1-（2-thenoyl）-3- [1- [4- （4-氟苯基）-4-氧代丁基]哌啶-4-基]脲（19和58）成为本系列中最有效的降压药。
• Anti-hypertensive benzodioxan derivatives
  申请人：Bouchara; Emile

  公开号：US04432984A1

  公开（公告）日：1984-02-21

  This invention relates to benzodioxanylalkylpiperidines, to processes for producing them and to the pharmaceutical compositions containing such compounds as active ingredient. This invention also relates to a method for treating hypertension in hypertensive mammals.

  本发明涉及苯二氧杂基烷基哌啶类化合物，涉及生产这些化合物的方法以及含有这些化合物作为活性成分的药物组合物。本发明还涉及一种治疗高血压的方法，适用于高血压哺乳动物。